Article
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Targeted oncology - 1 Mar 2015
Day Fiona, Muranyi Andrea, Singh Shalini, Shanmugam Kandavel, Williams David, Byrne David, Pham Kym, Palmieri Michelle, Tie Jeanne, Grogan Thomas, Gibbs Peter, Sieber Oliver, Waring Paul, Desai Jayesh
Abstract excerpt
The B-type Raf kinase (BRAF) V600E mutation is a well-established biomarker for poor prognosis in metastatic colorectal cancer (mCRC) and is a highly attractive drug target. A barrier to the development of new therapies targeting BRAF V600E in mCRC is the low prevalence of mutations (approximately 10 %) and the current need for access to sequencing-based technologies which are not routinely available outside of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.